世界の製薬ビジネスを伝える「Scrip」と、各国で変化する製薬関連の規制に特化した「Pink Sheet」。普段は英語で発信する2つのオンラインメディアから、今注目の話題を日本語で短くまとめてお届けします。

今回取り上げた記事はこちら 「Chinese Biotechs Ascend Deal-Making By Partnering Up Claudin 18.2 Agents（邦題意訳：中国バイオテック企業が急成長　CLDN18.2抗体で協業続々）」

https://scrip.pharmaintelligence.informa.com/SC147989/Chinese-Biotechs-Ascend-DealMaking-By-Partnering-Up-Claudin-182-Agents

世界の製薬業界ニュース Scrip（スクリップ）とは？
https://www.citeline.com/ja-jp/products-services/commercialization/scrip

Voice Recorder

【3分で解説  世界のファーマ】第9回 中国企業が急成長 CLDN18.2抗体市場のいま (Japanese-language podcast)

In the first episode of this new China Biopharma English-language mini podcast, Shanghai-based senior reporter Xu Hu looks at the main directions in which obesity drug developers are moving, Chinese pharma firms’ position in the global race for muscle-preserving weight loss drugs and China's challenge in matching accessible drugs with well-guided weight loss.

Related story links:

https://insights.citeline.com/scrip/r-and-d/chinese-developers-showcase-potentially-differentiated-weight-loss-assets-at-ada-TGCGQMCVBFHS7LNTWM6YDPEC3I/;

https://insights.citeline.com/in-vivo/global-vision/chinese-firms-build-obesity-clinical-pipeline-but-face-wider-hurdles-KX5GZJDC2NGKRDO6VUU7HROF4Y/


China Biopharma English-Language Podcast: Obesity Drugs Not All About Weight Loss

How is venture philanthropy revolutionizing Alzheimer's drug discovery? We sit down with Karen Harris, CFO at the Alzheimer's Drug Discovery Foundation, to explore their game-changing approach to funding early-stage research.

With $370M+ awarded to 765+ programs globally, the ADDF operates like a VC firm—using convertible debt and preferred equity to accelerate breakthrough treatments.
 
Topics:
Venture philanthropy vs traditional grants
Shift from amyloid to combination therapies
Blood-based biomarkers & precision medicine
NIH funding cuts impact on research ecosystem

Karen brings 20+ years investment banking experience to discuss how strategic capital is changing Alzheimer's research.

ADDF's Karen Harris: Investing in Alzheimer's Like a VC

世界の製薬ビジネスを伝える「Scrip」と、各国で変化する製薬関連の規制に特化した「Pink Sheet」。普段は英語で発信する2つのオンラインメディアから、今注目の話題を日本語で短くまとめてお届けします。
今回取り上げた記事はこちら

Snapshot Of India’s Pharma Manufacturing Network Amid ‘Trumponomics’（邦訳：インド、医薬品製造ネットワークの現在地　「トランプ経済政策」の最中で）
https://insights.citeline.com/scrip/focus-on-asia/india/snapshot-of-indias-pharma-manufacturing-network-amid-trumponomics-4NDNAVYZW5CPZIKDIZHDRXCJ6A/

※全文の閲覧には購読（有料）が必要です。
世界の製薬ビジネスメディアScrip（スクリップ）とは？
https://www.citeline.com/ja-jp/products-services/commercialization/scrip

 

【3分で解説  世界のファーマ】第24回 トランプ関税 製薬大国インドへの影響 (Japanese-language podcast)

Audio roundup of selected biopharma industry content from Scrip over the business week ended July 4, 2025. In this episode: AbbVie’s big autoimmune CAR-T play; In Vivo CAR-T interest grows; China deal perspectives from BIO; global pharma interest in Korea undeterred; and a look at the biggest drug sales disappointments.  
https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-Y77FXMFAIFEVFK75G5QUSNSBOY/

This episode was produced with the help of AI text-to-voice and voice emulation tools.

Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Scrip's Five Must-Know Things - July 7, 2025

According to a recently published study by Bayer Consumer Health, being poor makes it more likely that you will suffer from self-treatable health conditions. But it also means you will find it harder to take advantage of self-care solutions. In this episode of the Over the Counter podcast, HBW Insight speaks to Bayer Consumer Health’s global medical access lead Emese Csoke about the issues that the study raises for the self-care industry, not least how widening access to self-care solutions can be balanced with equity with regards to affordability. For Csoke, ways forward include partnerships between public and private sector stakeholders and investments in digital self-care. 

Timestamps
2:00 – Introductions
2:50 – Bayer Consumer Health’s RISE initiative 
4:00 – Self-care is hardest for those who need it most
5:45 – Implications for the consumer health industry
8:20 – Self-care’s “double burden”
10:15 – Profit vs people?
16:30 – Public-private partnerships
19:00 – Digital self-care
22:40 – Impact of RISE so far

Guest Bio
Emese Csoke is currently serving as global strategy director for regulatory, medical, safety, quality, and compliance at Bayer Consumer Health. In this role, she plays a pivotal part in advancing health equity by designing and implementing strategic initiatives that expand access to self-care. Emese led the creation of the strategic pillar RISE – the Research Initiative for Self-care Equity – and authored a peer-reviewed publication on the impact of socioeconomic determinants on health outcomes for self-care conditions. As a lead on Bayer’s “dynamic shared ownership” model, Csoke is also driving force behind organizational transformation and innovation. Csoke holds a PharmD and a degree in Clinical Development Science from Semmelweis University and is certified as a medical science translator.

How To Balance Access And Equity In Self-Care, With Bayer’s Emese Csoke

The latest episode of the In Vivo podcast features an conversation with Agnès Arbat, CEO and co-founder of Barcelona-based biotech company OxoLife, which is pioneering a novel approach to addressing female infertility.

Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

Ying Tam, Chief Scientific Officer at Acuitas Therapeutics, discusses the company's role in delivering the first personalized CRISPR gene editing treatment to an infant with CPS-1, achieving treatment in just six months from diagnosis. Tam shares insights on evolving lipid nanoparticle technology beyond COVID vaccines, including LNPs that allow for next-generation immune-targeting delivery that is 10x more potent, and progress in delivering genetic medicines to stem cells and solid tumors. He also addresses the challenges of repeat dosing, a new biodegradable LNP formulation, and expanding genetic medicine beyond the liver to treat blood disorders and cancer.

Acuitas CSO on CRISPR Delivery Breakthrough and Innovations in Lipid Nanoparticles

The latest episode of the In Vivo podcast features an interview with Phil L'Huillier, who discusses the inclusion of Scancell's melanoma cancer vaccine on the NHS Cancer Vaccine Launch Pad, and how 2025 could be a pivotal year for the cancer vaccine field as a whole. 

Phil L'Huillier, Scancell CEO, on the Latest Developments in Cancer Vaccines

올해 제약바이오 M&A 가 다소 주춤할 것으로 전망되고 있지만,  재정난을 겪고 있는 의약품 개발업체들이 자금조달의 대안을 찾으면서 잠재적 매물이 넘쳐나고 있다는 Scrip의 BIO USA 기사를 요약한 내용입니다.

https://insights.citeline.com/scrip/conferences/bio/bio-deal-trends-financial-market-stress-creates-transactional-opportunities-IL5W6U4BSZD6RPQ53EHG7HNTJ4/

 Playlist: soundcloud.com/citelinesounds/sets/korean-language-biopharma-mini

 

바이오 USA: 금융 시장 스트레스, 딜메이킹 기회 창출 (Korean-language podcast)

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.

【3分で解説世界のファーマ】第9回中国企業が急成長 CLDN18.2抗体市場のいま (Japanese-language podcast)

Citeline

Related tracks

【3分で解説 世界のファーマ】第9回 中国企業が急成長 CLDN18.2抗体市場のいま (Japanese-language podcast)

Citeline

Related tracks

【3分で解説世界のファーマ】第9回中国企業が急成長 CLDN18.2抗体市場のいま (Japanese-language podcast)